Journal of Innovations in Pharmaceutical and Biological Sciences
Read the article
Visual summary · Journal of Innovations in Pharmaceutical and Biological Sciences

Systems Pharmacology and Molecular Docking Investigation of Zingerone and Ellagic Acid as Potential Therapeutics for Oral Carcinogenesis

Shingare Shailesh, Shaikh Zaid Rashid, Shaikh Mehmood Dawood

The question

Could Zingerone and Ellagic Acid, taken together, act on several targets at once in oral carcinogenesis?

  • Oral carcinogenesis runs through many steps, among them oxidative stress, lasting inflammation, disordered cell growth, resistance to apoptosis, angiogenesis and spread to other sites.
  • Even with advances in chemotherapy and targeted medicines, treating oral cancer stays hard: toxicity through the body, resistance to drugs and a poor outlook.
  • Plant chemicals able to act on several targets have therefore drawn much interest in cancer research.

What was done

Twoplant compounds: Zingerone and Ellagic Acid
Networkpharmacology, to find shared targets
KEGGpathway study, with Gene Ontology enrichment
  • The study set out to judge what the two plant compounds might do together against oral carcinogenesis, using computational techniques brought together.
  • Network pharmacology was used to find the molecular targets shared with oral cancer.
  • Protein-protein interaction work, Gene Ontology enrichment and the study of KEGG pathways followed, to make the molecular mechanisms clearer.

Key findings

Finding 1 of 3
PI3K/Akt
and ERBB signalling were among the pathways involved

Pathways tied to oxidative stress, to inflammation, to apoptosis, to angiogenesis and to tumour growth were considerably involved, among them PI3K/Akt and ERBB signalling.

Finding 2 of 3
-8.6 kcal/mol
binding of Ellagic Acid to EGFR, above that of Erlotinib

Ellagic Acid bound EGFR at -8.6 kcal/mol; its binding to ERBB2 was -7.5 kcal/mol. Both affinities were higher than those of the conventional medication Erlotinib, and the ligand-protein interactions lasted.

Finding 3 of 3
Zingerone
also showed good binding with EGFR and ERBB2

Zingerone too showed good binding with the two target proteins.

Why it matters

  • The authors say the results show that Zingerone and Ellagic Acid together could be a promising strategy against oral carcinogenesis, acting on several targets at once.
  • The study worked by integrated computational techniques, with network pharmacology for the shared targets.

How to cite

Shingare Shailesh, Shaikh Zaid Rashid, Shaikh Mehmood Dawood. Systems Pharmacology and Molecular Docking Investigation of Zingerone and Ellagic Acid as Potential Therapeutics for Oral Carcinogenesis. Journal of Innovations in Pharmaceutical and Biological Sciences. 2026;13(01):56-66. https://doi.org/10.56511/jipbs.2026.13107

Open the article